TMCI compared with KYNB: revenue, margins and what each company keeps, and the suppliers and customers both name

TMCITreace Medical Concepts, Inc.

Mkt capRevenueRevenue

KYNBKyntra Bio, Inc.

Mkt capRevenueRevenue

Compare

TMCITreace Medical Concepts, Inc.

KYNBKyntra Bio, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

TMCI: latest quarter is a loss; flow not drawable. KYNB: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only TMCI 1

—MIOS Marketing, LLC d/b/a RedPoint Medical3D ("RPM-3D")unlistedsupplier

Shared 0

No shared counterparties.

Only KYNB 10

AZNAstraZeneca AB ("AstraZeneca")customer

—Astellas Pharma Inc. ("Astellas")unlistedsupplier

—Fortis Therapeutics, Inc. ("Fortis")unlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

Shanghai SynTheAll Pharmaceutical Co., Ltd. ("WuXi STA")

unlistedsupplier

6 more · KYNB chain ›

TMCITreace Medical Concepts, Inc.

4.28▼−0.02%· post 4.50

Mkt cap$292.7MRevenue$45MQ2 FY26Revenue$213MFY25

KYNBKyntra Bio, Inc.

4.15▼−3.71%· post 4.15

ClosedNov 4 '26

Mkt cap$17.5MRevenue$4MQ1 FY26Revenue$6MFY25

Compare

ClosedNov 4 '26

TMCITreace Medical Concepts, Inc.

KYNBKyntra Bio, Inc.

4.28▼−0.02%post 4.50

Price

4.15▼−3.71%post 4.15

$292.7M

Mkt cap

$17.5M

Q2 FY26$45M

Revenue

$4MQ1 FY26

FY25$213M

Revenue

$6MFY25

TMCI4.28▼−0.02%vsKYNB4.15▼−3.71%ClosedNov 4 '26

Price

rebased to 0%

TMCI, solidKYNB, dashed